PrescrAIP: A Pan-European Study on Current Treatment Regimens of Auto-Immune Pancreatitis
Frontiers in Medicine , Volume 7
Introduction: Treatment of autoimmune pancreatitis (AIP) is based solely on consensus and has yet to become standardized. Consequently, therapeutic regimens vary greatly between countries and centers, and largely depend on the experience of the physician. At this moment, the optimal regimen for inducing disease remission and preventing relapse is unknown. Objectives: The primary objective of this study is to describe current treatment regimens used in Europe, and to compare their effectiveness in inducing remission and preventing and treating relapse. The secondary objectives are: to identify risk factors for relapse; to assess the diagnostic accuracy of the Unified-AIP criteria; to assess the performance of the M-ANNHEIM score for predicting relapse; and to assess long-term outcomes including pancreatic exocrine insufficiency and pancreatic cancer. Methods: This is an international, retrospective, observational cohort study, performed in over 40 centers from 16 European countries. Eligible are all patients diagnosed with AIP from 2005 onwards, regardless of the used diagnostic criteria. Data on study subjects will be retrieved from the hospital's electronic medical records and registered with a standardized, web-based, electronic case report form (eCRF). To compare the effectiveness of treatment regimens in inducing remission, preventing relapse, and treating relapse, subjects will be stratified in groups based on: type of therapy; initial therapy dose; cumulative therapy dose; therapy tapering speed and duration; and having received maintenance therapy or not. Ethics and Dissemination: Ethical and/or institutional review board approvals are obtained by all participating centers according to local regulations. The study complies with the General Data Protection Regulation (GDPR). All manuscripts resulting from the study will be submitted to peer-reviewed journals. Conclusion: This is the first pan-European retrospective registry for AIP. It will produce the first large-scale data on treatment of European patients with AIP, providing answers on the use and effectiveness of treatment regimens. In the future, this collaboration may provide a network for continuation into a prospective European registry.
|autoimmune pancreatitis, cohort studies, glucococorticoids, IgG4, IgG4 (autoimmune pancreatitis)|
|Frontiers in Medicine|
|Organisation||Department of Gastroenterology & Hepatology|
Lanzillotta, M. (Marco), Vinge-Holmquist, O. (Olof), Overbeek, K.A. (Kasper A.), Poulsen, J.L. (Jakob L.), Demirci, A.F. (A. Fatih), Macinga, P. (Peter), … Rosendahl, J. (Jonas). (2020). PrescrAIP: A Pan-European Study on Current Treatment Regimens of Auto-Immune Pancreatitis. Frontiers in Medicine, 7. doi:10.3389/fmed.2020.00408